To include your compound in the COVID-19 Resource Center, submit it here.

Collecting Nektar

Why Nektar could attract a buyer despite its recent run-up

Given the potential of NKTR-214 to broaden the reach of checkpoint inhibitors, four buysiders who spoke with BioCentury said they would not be surprised to see Nektar Therapeutics (NASDAQ:NKTR) acquired, despite the 130% run-up in the company’s stock in recent months.

“It has

Read the full 420 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers